Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.278
-0.002 (-0.68%)
At close: Apr 28, 2026, 4:00 PM EDT
0.276
-0.002 (-0.75%)
Pre-market: Apr 29, 2026, 8:42 AM EDT
Mereo BioPharma Group Stock Forecast
MREO's stock price has decreased by -88.87% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Mereo BioPharma Group stock have an average target of 1.50, with a low estimate of 0.50 and a high estimate of 3.00. The average target predicts an increase of 438.99% from the current stock price of 0.28.
Analyst Consensus: Buy
* Price targets were last updated on Jan 16, 2026.
Analyst Ratings
The average analyst rating for Mereo BioPharma Group stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 0 | 0 |
| Hold | 0 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 23, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $1 | Strong Buy | Reiterates | $1 | +259.32% | Jan 16, 2026 |
| Needham | Needham | Strong Buy Maintains $5 → $3 | Strong Buy | Maintains | $5 → $3 | +977.97% | Jan 13, 2026 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $7 → $0.5 | Strong Buy → Hold | Downgrades | $7 → $0.5 | +79.66% | Dec 30, 2025 |
| BTIG | BTIG | Strong Buy Maintains $6 → $1 | Strong Buy | Maintains | $6 → $1 | +259.32% | Dec 29, 2025 |
Financial Forecast
Revenue This Year
26.42M
from 500.00K
Increased by 5,184.20%
Revenue Next Year
41.09M
from 26.42M
Increased by 55.51%
EPS This Year
-0.03
from -0.26
EPS Next Year
-0.00
from -0.03
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 52.5M | 109.9M | ||||||
| Avg | 26.4M | 41.1M | ||||||
| Low | n/a | 303,800 |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10,400.0% | 315.9% | ||||||
| Avg | 5,184.2% | 55.5% | ||||||
| Low | - | -98.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.02 | 0.13 | ||||||
| Avg | -0.03 | -0.00 | ||||||
| Low | -0.06 | -0.07 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.